Clinical trials: Thalidomide
Multiple Myeloma
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have…
- Trial name
- NCT00869232
- Testing
- Velcade, Melphalan, Thalidomide
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Arkansas
Pain, Chronic, Pain
Understanding and Managing Pain for Thalidomide Survivors
Aim: To explore the pain experience of Thalidomide survivors and propose an effective pain management service, tailored to meet the unique needs of this population.
- Trial name
- TRIUMPH-TS (NCT06398132)
- Testing
- Usual Care
- Where
- United Kingdom
- Volunteers
- 73 people
- Sponsor
- University of Nottingham
Multiple Myeloma
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies.
- Trial name
- NCT04891744
- Testing
- Selinexor, Thalidomide, Dexamethasone
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Li Zheng
B-Cell Lymphoma, Hodgkin's Disease
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma.
- Trial name
- NCT00209014
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Cardiac Amyloidosis
Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
To prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement
- Trial name
- TaPiOCA (NCT02966522)
- Testing
- Thalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Melanoma (Skin)
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Thalidomide may stop the growth of melanoma by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00104988
- Testing
- temozolomide, thalidomide
- Where
- 132 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Medulloblastoma Recurrent, Ependymoma Recurrent
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy…
- Conditions
- Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
- Trial name
- MEMMAT (NCT01356290)
- Testing
- Bevacizumab, Thalidomide, Celecoxib
- Where
- 22 sites in United States, Austria and 6 more
- Volunteers
- 232 people
- Sponsor
- Medical University of Vienna
Brain and Nervous System, Cancer
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2.
- Trial name
- NCT00251797
- Testing
- Irinotecan, Thalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma.
- Trial name
- NCT00006890
- Testing
- prednisone, thalidomide
- Where
- 64 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Radiation Injuries
The Therapeutic Effect of Thalidomide in RI
Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in radiation-induced brain injury.
- Trial name
- NCT03208413
- Testing
- Thalidomide
- Where
- 3 sites in China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Multiple Myeloma
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
In this study, the investigators will analyze the long-term outcomes of remission and survival, and identify those with primary resistant disease as more likely to benefit from CTD (thalidomide, cyclophosphamide, dexamethasone)…
- Trial name
- KMM-97 (NCT01114048)
- Testing
- Thalidomide, cyclophosphamide, dexamethasone, bortezomib
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Chonnam National University Hospital
Newly Diagnosed, Multiple Myeloma
Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in very elderly patients.
- Trial name
- IFM 01/01 (NCT00644306)
- Testing
- Thalidomide, melphalan, prednisone, melphalan, prednisone, thalidomide
- Where
- France
- Volunteers
- 232 people
- Sponsor
- Central Hospital, Nancy, France
Hepatocellular Carcinoma
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
This is a prospective, multicenter, randomized, open-label phase 3 study evaluating the efficacy and safety of transarterial chemoembolization (TACE) combined with a triple oral cocktail regimen versus TACE combined with targeted…
- Trial name
- Cocktail-001 (NCT07309419)
- Testing
- Apatinib, Camrelizumab, TACE
- Volunteers
- 222 people
- Sponsor
- Shanghai Zhongshan Hospital
Relapsed or Refractory Systemic Light Chain Amyloidosis
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB…
- Trial name
- NCT01659658
- Testing
- IXAZOMIB, Dexamethasone, Melphalan
- Where
- 66 sites in United States, Australia and 13 more
- Volunteers
- 177 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer.
- Trial name
- NCT00028886
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 450 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Leukemia
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
- Trial name
- NCT00083694
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Arkansas
Systemic Lupus Erythematosus
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
This pooled analysis will assess data from the Phase 3 belimumab registration studies BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and agreed prior to the unblinding of either study.
- Trial name
- NCT01914770
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Volunteers
- 1,016 people
- Sponsor
- GlaxoSmithKline
Oral Cavity Cancer
A Study of High-Risk Oral Cavity Cancer
Objectives: 1. To study the effect of anti-angiogenesis therapy on reducing the recurrence of high-risk oral cavity cancer patients after curative local treatment. 2.
- Trial name
- NCT00934739
- Testing
- Thalidomide, Celebrex, Cyclophosphamide, Dexamethasone
- Volunteers
- 150 people
- Sponsor
- National Health Research Institutes, Taiwan
Non-small-cell Lung Cancer
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung cancers.
- Trial name
- NCT04382300
- Testing
- pyrotinib combined with thalidomide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Chest Hospital
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
RATIONALE: Giving thalidomide together with prednisone and cyclophosphamide may lessen symptoms caused by myelofibrosis and myeloid metaplasia.
- Trial name
- NCT00445900
- Testing
- cyclophosphamide, prednisone, thalidomide
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic